Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We investigated a novel therapeutic target through screening FDA‐app...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:EMBO Mol Med
मुख्य लेखकों: Yun, Mi Ran, Choi, Hun Mi, Lee, You Won, Joo, Hyeong Seok, Park, Chae Won, Choi, Jae Woo, Kim, Dong Hwi, Kang, Han Na, Pyo, Kyoung‐Ho, Shin, Eun Joo, Shim, Hyo Sup, Soo, Ross A, Yang, James Chih‐Hsin, Lee, Sung Sook, Chang, Hyun, Kim, Min Hwan, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2019
विषय:
Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895608/
https://ncbi.nlm.nih.gov/pubmed/31633304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910581
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन